Get access to our best features
Get access to our best features
Published 2 months ago

Pfizer to seek approval for RSV vaccine for people as young as 18

  • Pfizer's RSV vaccine, Abrysvo, demonstrated a strong immune response in adults aged 18 to 59, protecting against RSV-associated illness.
  • The vaccine trial included adults with underlying chronic conditions like asthma and diabetes, who are at higher risk of RSV.
  • Hawaii Department of Health is investigating cases of pertussis, a highly contagious respiratory illness causing severe coughing fits and other complications.
Insights by Ground AI
Does this summary seem wrong?

0 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 64% of the sources are Center
68% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)